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Background: Alkaloids present in plants of the Amaryllidaceae family are secondary metabolites of high biological
interest, possessing a wide range of pharmacological activities. In the search for new plant-derived compounds with
antimicrobial activities, two alkaloid extracts obtained from bulbs and leaves of Pancratium illyricum L., a plant of the
Amarillydaceae family, were tested for their effect on bacterial and yeast growth.
Methods: The broth microdilution susceptibility test was applied to study the effect of plant extracts on the growth of
reference bacterial strains and Candida albicans reference and clinical isolates strains. Extracts obtained from the different
parts of the plant were tested and compared with the pure components identified in the extracts. Since matrix
metalloproteinase enzymes play a role in the dissemination process of Candida albicans, the effect of the bulb
extract and pure alkaloids on in vitro collagenase activity was tested. Cell viability test was carried out on human
embryo lung fibroblasts (HEL 299).
Results: Whilst both extracts did not show any inhibitory activity against neither Gram positive nor Gram negative
bacteria, a strong antifungal activity was detected, in particular for the bulb extract. All clinical isolates were susceptible
to the growth inhibitory activity of the bulb extract, with endpoint IC50 values ranging from 1.22 to 78 μg/mL. The pure
alkaloids lycorine and vittatine, identified as components of the extract, were also assayed for their capacity of
inhibiting the yeast growth, and lycorine turned very active, with endpoint IC50 values ranging from 0.89 to 28.5 μg/mL.
A potent inhibition of the in vitro collagenase activity was found in the presence of the bulb extract, and this effect was
much higher than that exerted by the pure alkaloids. Viability of cell lines tested was not affected by the extract.
Conclusions: Taken together, results suggest that the extract of Pancratium illyricum may act as antifungal agent both
directly on the yeast growth and by altering the tissue invasion process.
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Candida albicans is an important pathogen of humans
characterized by a high versatility. The yeast is a com-
mensal in several anatomically distinct sites and, under an
extensive variety of predisposing factors (ranging from
specific immune defects to mucosal or cutaneous barrier
disruption, ageing, diabetes, AIDS), it can invade tissues
leading to a wide spectrum of clinical symptoms.
Among the early events in the pathogenesis of candid-
iasis there are the adhesion of the yeast cells to host cells,
the yeast-hyphal transition, with changes in antigen expres-
sion and tissue affinities, and the direct persorption into
the submucosa [1]. Subsequently, for the dissemination, C.
albicans can affect host matrix metalloproteinases (MMPs)
expression, mainly MMP-9, leading to tissue degradation
and inflammatory processes [2].
MMPs are a family of secreted or cell surface-associated
proteolytic enzymes targeting almost all extracellular matrix
(ECM) components and basement membrane proteins
[3]. MMPs have been classified according to their substrate
specificities and are often referred to as collagenases,
gelatinases, stromelysins, matrilysins, and membrane-type
MMPs. The catalytic domain of all MMPs contains a zinc-
binding motif, an additional structural zinc ion, and 2–3
calcium ions, which are required for the stability and the
expression of enzyme activity [4]. To date, many extracts
or compounds from plant origin have been studied as pos-
sible inhibitors of some MMPs as the modulation of their
expression has been implicated in inflammatory disorders,
cancer invasion, metastasis, and microbial infections [5,6].
Concerning antifungal therapy, candidiasis are widely
treated with triazole drugs (fluconazole, voriconazole, itra-
conazole, and posaconazole) that inhibit the biosynthesis of
the ergosterol, the major sterol in the fungal plasma
membrane. However, their extensive use has raised con-
cern about resistant infections that negatively impact the
clinical outcome mainly for high risk patients and those
with persistent mycoses [7].
In the search for naturally derived compounds with
promising antimicrobial activities, a particular focus was
recently given to the alkaloids produced by plants of the
Amaryllidaceae family. Indeed, the Amaryllidaceae alka-
loids are secondary metabolites of high biological inter-
est, possessing, among others, antimicrobial, antitumoral
and acetylcholinesterase inhibitory activities [8-10]. Several
species of Crinum have already been proven for their anti-
bacterial and antifungal activities. For instance, the alkaloid
crinamine isolated from bulbs of C. jagus showed strong
inhibitory activity against Staphylococcus aureus [11], and
in vitro activity against C. albicans was demonstrated
for C. macowanii extract [12]. Alkaloids present in C.
angustum Steud [13] and C. purpurascens [14] were
also reported to possess antibacterial and antifungal
activities.In the present study, a set of 30 C. albicans clinical
isolates was tested to explore the antifungal activity of an
alkaloid extract of Pancratium illyricum L., a species en-
demic to Sardinia, Corsica and the Tuscan archipelago [15];
the in vitro anti-collagenase activity and the mechanism of
action of P. illyricum extract towards the collagenase
enzyme were also investigated.
This work was aimed at finding new antifungal agents
having anti-collagenase activity, which may also affect
the yeast virulence, in a combined effect with growth
inhibition.
Methods
Clinical isolates
The study included 30 C. albicans clinical isolates recov-
ered from urine samples, collected at S. Orsola-Malpighi
Hospital, Bologna (Italy). All isolates were cultured on
CHROMagar Orientation Medium (Becton Dickinson,
Heidelberg, Germany), then species identification was
carried out by standard procedures, including colony
morphology on chromogenic agar (CHROMagar Candida
Medium, Becton Dickinson), and confirmed by MALDI
Biotyper System using matrix-assisted laser desorption
ionization–time of flight mass spectrometry (MALDI-
TOF MS, Bruker Daltonik, GmbH, Germany) [16].
Plant material
Pancratium illyricum L. was collected during the flower-
ing period (May 2011) in the South of Sardinia (Punta San
Michele, CA, Italy), and identified by Professor Mauro
Ballero (University of Cagliari, Italy). A voucher specimen
(CAG 1365) has been deposited in the Institute of Botany,
University of Cagliari.
Extraction and isolation of pure alkaloids
An extract enriched in alkaloids was prepared from bulbs
and leaves separately. Fresh plant material (298 g and 168 g,
respectively) was crushed in small pieces and exhaustively
extracted with MeOH at room temperature for 72 h. The
extracts were evaporated under reduced pressure to yield
15.85 g and 10.17 g for bulbs and leaves, respectively. These
crude extracts were acidified by dissolving in 100 mL H2SO4
1% (v/v) and neutral material was removed with n-hexane
(6 × 100 mL) and chloroform (CHCl3, 4 × 100 mL). The
acidified solution was then basified with 25% NH4OH up to
pH 9–10 and extracted with CHCl3 (4 × 100 mL) to give the
CHCl3 extract containing alkaloids (130 mg for bulbs and
120 mg for leaves). Both extracts were dried with anhydrous
Na2SO4, filtered and completely dried under reduced pres-
sure. The extract yields, on a fresh weight basis, were 0.05%
for bulbs and 0.07% for leaves. The CHCl3 bulb extract was
then subjected to vacuum liquid chromatography (VLC)
[13] using a silica gel 60 Å (6–35 μm) column (1 cm diam-
eter and 4 cm height). Alkaloids were eluted using n-hexane
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enriched with CHCl3 and finally with a mixture of EtOAc
and CHCl3 gradually enriched with MeOH. Fractions of
10 mL were collected (200 in total), monitored by TLC
(Dragendorff ’s reagent, UV 254 nm) and combined accord-
ing to their profiles. Nine main fractions were obtained and
subjected to preparative TLC (20 cm× 20 cm× 0.25 mm,
silica gel 60 F254). Crystals of lycorine and vittatine soluble
compounds were obtained in major quantities from frac-
tions 128–133 (eluted from VLC with n-Hexane-EtOAc-
CHCl3, 20:60:20 to 15:60:25). Crystals of lycorine (20 mg)
were collected as needles by separating from the solvent
and then subjected to GC-MS analysis to confirm the
alkaloid identity. Vittatine (7 mg) was obtained through
preparative TLC from collected fractions (EtOAc-CHCl3-
CH3OH 3:1:1 + 25% ammonia).
EIMS were obtained on a GC-MS Hewlett-Packard
6890 +MSD 5975 operating in EI mode at 70 eV. A HP-5
MS column (30 m × 0.25 mm × 0.25 μm) was used. The
temperature program was: 100–180°C at 15°C min-1,
1 min hold at 180°C, 180–300°C at 5°C min-1 and 1 min
hold at 300°C. Injector temperature was 280°C. The flow
rate of the carrier gas (helium) was 0.8 mL min-1.
The compounds of the final CHCl3 extracts of bulbs
and leaves, and the pure compounds lycorine and vittatine,
were identified as TMS with the help of the NIST 05 data-
base (NIST Mass Spectral Database, PC-Version 5.0, 2005,
National Institute of Standardisation and Technology,
Gaithersburg, MD, USA), and other plant-specific data-
bases: the Golm Metabolome Database (http://csbdb.
mpimp-golm.mpg.de/csbdb/gmd/home/gmd_sm.html),
on the basis of matching mass spectra and Kovats re-
tention indexes (RI). The measured mass spectra were
deconvoluted by the Automated Mass Spectral Decon-
volution and Identification System (AMDIS 2.64, NIST
Gaithersburg, MD) before comparison with the databases.
RI values of the compounds were measured with stand-
ard n-hydrocarbon calibration mixture (C9–C36; Restek,
Bellefonte, PA, USA, catalogue no. 31614, supplied by
Teknokroma, Spain) using AMDIS 2.64 software. Additional
files 1, 2, 3, 4, 5, 6 and 7 show the GC-MS profile of the bulb
extract and pure compounds identified.Susceptibility testing
Preliminary experiments were performed on standard
American Type Culture Collection (ATCC) strains:
Staphylococcus aureus ATCC 25923, Staphylococcus
epidermidis ATCC 12228, Escherichia coli ATCC 25922,
Klebsiella pneumoniae ATCC 9591, and on C. albicans
ATCC 10231.
Bacteria strains were assayed with the alkaloid extracts
of P. illyricum, from bulbs and leaves (12 dilutions; range
0.156 to 312 μg/mL), and gentamicin (Sigma-Aldrich,Saint Louis, USA) as reference drug control, by means of a
previously described broth microdilution protocol [13].
All yeast strains were assayed with the alkaloid extracts
of P. illyricum, from bulbs and leaves, (12 dilutions; range
range 0.156 to 312 μg/mL), the pure compounds lycorine
and vittatine (12 dilutions; range 0.03 to 114 μg/mL and
0.05 to 225 μg/mL, respectively) and amphotericin B (12
dilutions; range 0.002 to 5 μg/mL). Amphotericin B was
supplied from Sigma (Sigma-Aldrich, Saint Louis, USA).
Inocula of all Candida isolates and two-fold microdi-
lution broth method were performed according to the
European Committee on Antimicrobial Susceptibility Test-
ing (EUCAST) guidelines [17]. Briefly, the inoculum was
prepared by suspending a maximum of 5 distinct colonies
in 5 mL of sterile 0.9% saline solution, then density was
adjusted at 0.5 McFarland by measuring the absorbance
(DU-530 UV–vis Spectrophotometer, Beckman Coulter,
Inc., CA, USA). Finally, a working suspension was pre-
pared from a 1:10 dilution of the standardized suspension
in RPMI-1640 medium (Gibco®, Thermo Fisher Scientific
Inc., Waltham, USA), containing glucose 2%, 0.3% levo-
glutamine, 0.165 M 3-(N-morpholino)-propanesulfonic acid
(MOPS), pH 7.0, to yield 1–5 × 105 CFU/mL.
Each well of a 96-well microplate was inoculated with
100 μL of the yeast suspension and with 100 μL of the
testing drugs, serially two-fold diluted in RPMI-1640
medium. Growth control wells containing 100 μL of sterile
drug-free medium and 100 μL of the same inoculum were
also prepared, as well as negative control wells. Finally,
solvent controls were prepared by serially diluting DMSO
(12 dilutions; starting from 3.12%) to measure its interfering
effect on yeast growth. Each strain and all controls were
tested in triplicate. The microdilution plates were incubated
at 37°C for 24 h, without agitation, and subsequently the
absorbance at 530 nm was measured by the Multiskan
Ascent microplate reader (Thermo Fisher Scientific Inc.,
Waltham, USA). The growth inhibition of the yeast cells
was calculated and expressed as MIC (minimum inhibitory
concentration) and IC50 (concentration required for a
growth reduction of the 50%).
The minimal fungicidal concentrations (MFCs) were
determined by subculturing 50 μL of supernatants from the
wells where no growth was observed in broth microdilution
plates, previously described. The samples were cultured
on Sabouraud agar plates (Becton Dickinson, Heidelberg,
Germany) and incubated at 37°C for 24 h. The MFC was
the lowest drugs concentration that showed either no
growth or fewer than 3 colonies to obtain approximately
99 to 99.5% killing activity [18]. The MFC was determined
from three independent experiments.
Anti-collagenase assay
The bulbs extract of P. illyricum and pure compounds,
lycorine and vittatine, were tested for their capacity of
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was based on a spectrophotometric method reported in the
literature [19], slightly modified for a 96-well microplate,
using Clostridium hystolyticum collagenase (EC.3.4.23.3)
and FALGPA (N-[3-(2-Furyl)acryloyl]-Leu-Gly-Pro-Ala) as
substrate. Enzyme was dissolved in 50 mM Tricine buffer
(containing 10 mM CaCl2 and 400 mM NaCl), pH 7.5, to
give 0.8 units/mL (according to the supplier’s activity data);
a 2 mM solution of substrate FALGPA was prepared in
the same buffer. Twenty-five μL buffer, 25 μL H2O or
inhibitor, and 25 μL enzyme were loaded into each well
of the microtplate, and after 15 min preincubation, 50 μL
of substrate were added. Absorbance was measured at
340 nm immediately and at 2-min intervals for 20 min. En-
zyme activity was estimated by following the decrease in
absorbance during the time interval due to substrate hy-
drolysis. Epigallocatechin gallate (EGCG) was used as posi-
tive control. Four substrate concentrations in the range
0.5 mM - 2.5 mM were assayed to elucidate the mechanism
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Figure 1 Representative dose–response curve of a Candida
albicans clinical isolate. Experimental IC50 values were obtained by
the interpolation of data on the specific dose–response curve, generated
by means of a nonlinear regression analysis. In particular, the reduction
of the yeast growth, expressed as percentage, was plotted against
the drug concentration, in logarithm scale, leading to the generation of
a sigmoidal curve following the equation Y = 100/(1 + 10^((LogIC50-X)
*HillSlope))), where Y =50.Cell viability testing
Cytotoxic effects of the bulbs extract of P. illyricum were
evaluated against the human embryo lung fibroblasts
(HEL 299) by using the commercially available alamarBlue
Assay (Life Technologies, Thermo Fisher Scientific Inc.,
Waltham, USA). Cells were grown in EMEM (Eagle’s
Minimum Essential Medium, Gibco®, Thermo Fisher
Scientific Inc., Waltham, USA) supplemented with 10%
fetal calf serum (Lonza, VWR International, Radnor, USA),
10 U of penicillin and 50 μg/mL streptomycin at 37°C and
5% CO2. For each set of experiments, cells were seeded at
the density of 104 cells/well in a 96-well culture microplate
and incubated with 100 μL of the extract at concentrations
ranging from 0.016 to 312 μg/mL diluted in complete
medium. In addition, cells were tested with dilutions
of amphotericin B (0.002 to 5 μg/mL) and DMSO (0.0015
to 3.12%). Positive controls containing cells in regular
medium were also included.
Cells were grown for 24 h at 37°C, then the medium
was discarded, cells were replenished with 100 μL of
new complete medium and 10 μL of the ready-to-use
alamarBlue reagent were added to wells. The ingredient,
resazurin (no-fluorescent form), is a cell permeable com-
pound that, upon entering cells, is reduced to resorufin
(fluorescent form) as cellular innate metabolic activity re-
sults. Reduction of alamarBlue was quantitatively evalu-
ated following a 4 and 24 h of incubation by fluorescence
measurement at the Varioskan Flash Multimode Reader
(Thermo Fisher Scientific Inc., Waltham, USA) using a
fluorescence excitation peak at 570 nm and emission peak
at 585 nm. All determinations were confirmed by replica-
tion of three experiments.Data analysis
The antifungal activities of the P. illyricum, bulbs and leaves,
pure compounds (lycoyine and vittatine), and amphotericin
B, as reference control, were evaluated by the determination
of the MIC, corresponding to the lowest concentration giv-
ing rise to an inhibition of yeast growth ≥90% of that of the
solvent DMSO or drug-free controls. Moreover, two IC50
values were calculated for each tested reagent: an endpoint
IC50, defined as the lowest drug concentration leading to a
yeast growth reduction of the 50%, and an experimental
IC50, obtained by the interpolation of growth data on
dose–response curves (Figure 1). These curves were de-
termined by plotting the percentages of growth inhib-
ition, relative to the solvent or to the positive growth
controls, as function of the 12 tested concentrations (in
logarithm scale). Statistical analysis were carried out by
nonlinear regression method using GraphPad Prism ver-
sion 5.00 for Windows (GraphPad Software, San Diego
California, USA).
In the anti-collagenase assay the percentage inhibition
of enzyme activity was calculated by the following for-
mula: %inhibition = [1- (Δ Abs/min sample/Δ Abs/min
negative control) × 100]
IC50 (concentration necessary for 50% inhibition of en-
zyme activity) was calculated by constructing a linear re-
gression curve. A Lineweaver-Burk (L-B) plot was built
to calculate the kinetic parameters (Km expressed in
mM and Vmax in nmol/s) of the enzymatic reaction
without and with P. illyricum bulbs extract, at the IC50
concentration.
10
12
R2 = 0.932
s
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4 h and 24 h of incubation with the bulbs extract of P.
illyricum and amphotericin B. The reduction of the
non-fluorescent compound into a fluorescent form of
resorufin from living cells was quantitatively measured
and expressed as percentage of growth, relative to solvent
or positive HEL 299 controls. A growth inhibition ≥20%
was considered affecting cell proliferation [20].
Results
P. illyricum extracts and pure compounds
Bulb and leaf extracts from P. illyricum were found to
possess a slightly different alkaloid profile, as reported in
Iannello et al. [13]. In particular, besides the presence of
common alkaloids found in both organs of the plant, some
exclusive alkaloids only present in leaves were reported.
Lycorine and vittatine turned to be present in both plant
organs.
Antifungal activity
In a preliminary set of experiments, extracts from both
bulbs and leaves were assayed with conventional broth
microdilution susceptibility testings on reference bacteria
strains (Staphylococcus aureus ATCC 25923, Staphylococcus
epidermidis ATCC 12228, Escherichia coli ATCC 25922,
and Klebsiella pneumoniae ATCC 9591) and on C. albicans
ATCC 10231. Data obtained demonstrated that P. illyricum
extracts were completely uneffective against both Gram-
positive and Gram-negative bacteria, while turned ra-
ther active against C. albicans. Between the bulb and the
leaf extracts, the former showed a higher inhibitory effect
on the yeast growth compared to the latter (IC50 endpoint
39 and 78 μg/mL, respectively), and, as a consequence, it
was subjected to further investigations. Its effect was com-
pared to that of pure alkaloids lycorine and vittatine, and
with amphotericin B. Data on their activities are summa-
rized in Table 1.
All C. albicans clinical isolates proved to be susceptible
to the bulbs extract of P. illyricum, with endpoint IC50Table 1 Results of the antifungal activities of the bulbs
extract and its pure alkaloids
Antifungal activities
experimental IC50
(μg/mL)
endpoint IC50
(μg/mL)
MIC
(μg/mL)
P. illyricum bulbs 0.65 – 47 1.22 - 78 19.5 - 156
Lycorine 0.46 – 16.95 0.89 – 28.50 3.56 – 57
Vittatine - - -
Amphotericin B 0.02 – 0.23 0.039 – 0.625 0.078 – 1.25
The following range concentrations were used in the microdilution broth
methods: from 312 to 0.156 μg/mL for P. illyricum bulbs, from 114 to 0.03 μg/mL
for lycorine; from 225 to 0.05 μg/mL for vittatine and from 5 to 0.002 μg/mL for
amphotericin B.values and experimental IC50 values ranging from 1.22 to
78, and from 0.65 to 47 μg/mL, respectively. Moreover, the
frequency distribution of the endpoint IC50 was normally
distributed (R2 = 0.932) with a mean value of 48.94 μg/mL
and a 95% confident interval within 44.06 and 53.82 μg/
mL (Figure 2). These values, significantly lower than
100 μg/mL, perfectly comply with the criteria suggested
by Cos et al. [21], and demonstrate that bulbs possess a
relevant and selective activity against C. albicans strains.
The pure compounds, lycorine and vittatine, were assayed
against the yeast isolates in order to identify the main active
components in the alkaloid extract. C. albicans growths
were not inhibited by vittatine at the tested concentra-
tions (0.05–225 μg/mL), while lycorine potently reduced
yeast growth with endpoint IC50 values ranging from 0.89
to 28.50 μg/mL (3.10–99.19 μM). Experimental IC50
values for lycorine and bulbs extract were arranged
in a XY plot (Figure 3) displaying a linear correlation
(R2 = 0.949); this result suggests that this compound is
likely to contribute to the antifungal activity of the
total extract of P. illyricum.
After IC50 and MIC determinations, the MFCs were
measured by subculturing the supernatants from the
susceptibility testings. At the tested concentrations, both
P. illyricum extract and lycorine did not act as fungicidal
agents.
All C. albicans isolates were susceptible to the reference
amphotericin B drug with endpoint IC50 values and MICs
ranging from 0.039 to 0.625 μg/mL and 0.078-1.25 μg/mL,
respectively; MFCs were equal to MICs or two-folds
higher according to the behavior of a fungicidal agent [18].0.1 1 10 100 1000 10000
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Figure 2 Frequency distribution of IC50 values. The number of
observations were plotted as function of the endpoint IC50 values,
in logarithm scale; data follow a Gaussian distribution (R2 = 0.932).
0 10 20 30 40 50 60
0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5
20.0
R2 = 0.949
N = 30
P. illyricum [µg/mL]
Ly
co
rin
e 
[µ
g/
m
L]
Figure 3 Analysis of correlation between experimental IC50 values
obtained for P. illyricum and lycorine on Candida albicans clinical
isolates. A scatter plot was generated with the experimental IC50 values
obtained for P. illyricum bulbs and lycorine showing a positive linear
pattern (R2 = 0.949). Dotted lines indicate the 95% confident interval.
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P. illyricum bulb extract and pure compounds, lycorine
and vittatine, were tested for their inhibiting effect on
in vitro collagenase activity at an initial concentration
of 200 μg/mL; this is the maximum concentration that
can be tested with this extract without having any spec-
trophotometrical interference [19]. The highest anti-
collagenase activity was displayed by the whole extract,
reaching a 99.61% inhibitory activity, while the pure
compounds, at the same concentration, showed a much
lower inhibiting effect, being below 30%. The bulbs ex-
tract of P. illyricum was further investigated to determine
IC50 value, which turned out to be about six times higher
compared to EGCG, the reference compound for this
assay (Table 2). The mechanism of action of the bulb
extract towards inhibition of the collagenase enzyme
has been evaluated. To this purpose, the enzyme kinetics in
the absence and presence of the extract was followed, and a
Lineweaver-Burk plot was built, as shown in Figure 4.
Variation of Vmax and KM values in the presence of bulb
extract compared to the enzyme without inhibitor suggests
that the inhibition is of reversible- and uncompetitive-type.
Indeed, both values turned out to be reduced by about 50%
in the presence of the extract (Table 3), as a consequence
of the interaction with the enzyme-substrate complex.
Cell viability testing
The analysis of cellular health of HEL 299 cell line after
24 h of incubation with the alkaloid extract of P. illyricumTable 2 IC50 values of P. illyricum bulb extract, and of the
reference compound epigallocatechin gallate
IC50 (μg/mL) IC50 (μM)
P. illyricum bulbs 25.00 ± 0.1 -
EGCG 4.33 ± 0.02 9.45 ± 0.5bulbs was carried out by evaluating the natural reducing
power of living cells. The conversion of the substrate
resazurin in resorufin by metabolically active cells was
quantitatively measured at 4 and 24 h after adding the
alamarBlue reagent. Both data demonstrated that the
extract of P. illyricum did not interfere with the regular
cell proliferation at the tested concentrations (data not
shown).
Discussion and conclusions
The present study was aimed at evaluating the potential
of the alkaloid extract of P. illyricum bulbs as source for
novel antimicrobial agent. While no inhibitory activity was
found against bacteria, a good antifungal activity was ob-
served on C. albicans clinical isolates. In vitro susceptibility
assays were performed against 30 yeast strains concurrently
with the lycorine and vittatine, alkaloids mainly present in
the bulb, isolated and purified from the plant. The IC50
values for the bulbs, ranging from 0.65 to 47 μg/mL,
demonstrate the relevant antifungal activity of P. illyricum,
since they perfectly meet the stringent criteria for “activity”
established by Cos et al. [21]. The analysis of the pure com-
pounds allowed to identify the lycorine as the major ac-
tive component on the bulbs extract. Indeed, vittatine
was completely uneffective, while lycorine has a potent
inhibitory effect on fungal growth, with a mean experi-
mental IC50 value of 22.03 μM, again complying with the
threshold (<25 μM) suggested for pure compounds [21].
In addition, the experimental IC50 values significantly
correlate with those of the bulbs extract, corroborating
that lycorine mostly contributes to the biological activ-
ities observed against C. albicans clinical isolates. Our
results are in agreement with those obtained by other
researchers [8] indicating that lycorine is not active on
bacteria while is a potent inhibitor of C. albicans growth.
The inactivity of lycorine on some bacterial strains can be
explained by the fact that bacteria, as Staphylococcus
aureus, are able to transform lycorine in its inactive
metabolite 2-O-demethylungiminorine, instead of the active
ungeremine [22]. A recent study carried out on pathogenic
crop fungi suggests that lycorine may act by damaging cell
membranes, leading to the exosmosis of intracellular mate-
rials [23]. Consequently, substrate absorption and cell
metabolism are strongly affected.
In addition to the antifungal properties, the present
study investigated the activity of P. illyricum against col-
lagenase, enzyme belonging to the MMPs family [3]. Of
note, C. albicans holds a 95 kDa metallopeptidase in the
cell wall and produces extracellular proteinases, assisting
the pathogen in the infectious process [24-26]. The
identification of compounds with anti-metallopeptidase
activity, thus targeting yeast virulence, represents a crucial
step in the candidiasis drug development. Interestingly,
some antibiotics, such as tetracycline, are known for their
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Figure 4 Lineaweaver-Burk plot of Clostridium collagenase and FALGPA without (●) and with (■) P. illyricum bulb extract. Enzyme assay
was performed with a FALGPA concentration range of 0.5 – 2.5 mM.
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than for their direct action towards microorganisms.
The bulbs extract of P. illyricum markedly inhibited the
collagenase enzyme (99.61%), with an IC50 value directly
comparable with that of the reference standard (EGCG)
while the pure compounds displayed a moderate inhibi-
tory activity (30%), at the same enzyme concentration. In
this regards, it is possible to speculate that the extract is
more active than the purified compounds because, in the
former, there is a synergic action of several compounds
[28], and the anti-collagenase activity is not due solely to
the lycorine, differently from what observed for the anti-
fungal properties. The analysis of the mechanism of
inhibition of bulbs extract of P. illyricum towards the
collagenase enzyme reveals that the inhibition is of
reversible- and uncompetitive-type, thus suggesting that
an interaction with the enzyme-substrate complex occurs,
bringing to a higher affinity of the enzyme towards the
substrate. Thus, taken together, results obtained in the
present study suggest that alkaloid extract of P. illyricum
is a very attractive and auspicious candidate for antifungal
drug development since it combines two modes of action:
as conventional antimicrobial agents, the extract select-
ively interferes with yeast cell viability by inhibiting C.
albicans growth (−static action) and, as an added value,
it exhibits a marked anti-collagenase activity which may
target fungal virulence in the tissue invasion process.Table 3 Kinetic parameters on the enzyme inhibition
given by the extract of P. illyricum
Enzyme with extract Control
KM (mM) 0.189 0.372
Vmax (nmol/s) 0.017 0.033Additional files
Additional file 1: GC-MS chromatogram (TIC on Y-axis) of alkaloid
extracts in bulbs of Pancratium illyricum L. Conditions as reported
in the text. (A):_galanthamine, (B): sanguinine, (C): vittatine, (D):
habranthine, (E): lycorine, (F): leucotamine, (G): O-methylleucotamine,
(H): 2-hydroxyhomolycorine.
Additional file 2: GC-MS of galanthamine in bulb extract of
Pancratium illyricum L. and relative spectrum from library.
Additional file 3: GC-MS of sanguinine in bulb extract of
Pancratium illyricum L. and relative spectrum from library.
Additional file 4: GC-MS of vittatine in bulb extract of Pancratium
illyricum L. and relative spectrum from library.
Additional file 5: GC-MS of habranthine in bulb extract of
Pancratium illyricum L. and relative spectrum from library.
Additional file 6: GC-MS of lycorine in bulb extract of Pancratium
illyricum L. and relative spectrum from library.
Additional file 7: GC-MS of 2-hydroxyhomolicorine in bulb extract
of Pancratium illyricum L. and relative spectrum from library.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FB designed the work, performed the experiments and analyzed data. FA
designed the experiments and wrote the manuscript. CI designed the work
and performed experiments. AM collected the plant. FP and GAG designed
the work. The final manuscript was read and approved by all authors.
Acknowledgments
This research was supported by Basic Research Program FARB of Ferruccio
Poli (Finanziamenti di Ateneo per la Ricerca di Base, 2013) from the
University of Bologna.
Author details
1Department of Pharmacy and Biotechnology, University of Bologna, via
Massarenti 9, 40138 Bologna, Italy. 2Department for Life Quality Studies,
University of Bologna, Corso Augusto, 237, 47921 Rimini, Italy. 3Department
of Pharmacy and Biotechnology, University of Bologna, via Irnerio 42, 40126
Bologna, Italy. 4Interacademic Union for Studying of Secondary Metabolites
of Vegetal Origin (Co.S.Me.Se.), Viale Ignazio da Laconi 13, Cagliari, Italy.
Bonvicini et al. BMC Complementary and Alternative Medicine 2014, 14:409 Page 8 of 8
http://www.biomedcentral.com/1472-6882/14/409Received: 28 June 2014 Accepted: 16 October 2014
Published: 23 October 2014
References
1. Calderone RA, Fonzi WA: Virulence factors of Candida albicans.
Trends Microbiol 2001, 9:327–335.
2. Claveau I, Mostefaoui Y, Rouabhia M: Basement membrane protein and
matrix metalloproteinase deregulation in engineered human oral
mucosa following infection with Candida albicans. Matrix Biol 2004,
23:477–486.
3. Sterlicht MD, Werb Z: How matrix metalloproteinases regulate cell
behavior. Annu Rev Cell Dev Biol 2001, 17:463–516.
4. Nagase H, Woessner JF: Matrix metalloproteinases.
J Biol Chem 1999, 274:21491–21494.
5. Tate P, God J, Bibb R, Lu Q, Larcom LL: Inhibition of metalloproteinase
activity by fruit extracts. Cancer Lett 2004, 212:153–158.
6. Kumar MS, Kirubanandan S, Sripriya R, Sengal PK: Triphala promotes healing
of infected full-thickness dermal wound. J Sur Res 2008, 144:94–101.
7. Perlin DS: Antifungal drug resistance: do molecular methods provide a
way forward? Curr Opin Infect Dis 2009, 22:568–573.
8. Evidente A, Andolfi A, Abou-Donia AH, Touema SM, Hammoda HM, Shawky E,
Motta A: (−)-Amarbellisine, a lycorine-type alkaloid from Amaryllis
belladonna L. growing in Egypt. Phytochemistry 2004, 65:2113–2118.
9. Casu L, Cottiglia F, Leonti M, De Logu A, Agus E, Tse-Dinh YC, Lombardo V,
Sissi C: Ungeremine effectively targets mammalian as well as bacterial
type I and type II topoisomerases. Bioorg Med Chem Lett 2011, 21:7041–7044.
10. Iannello C, Pigni NB, Antognoni F, Poli F, Maxia A, de Andrade JP, Bastida J:
A potent acetylcholinesterase inhibitor from Pancratium illyricum L.
Fitoterapia 2014, 92:163–167.
11. Adesanya SA, Olugbade TA, Odebiyi OO, Aladesanmi JA: Antibacterial
Alkaloids in Crinum jagus. Inter J Pharmacog 1992, 4:303–307.
12. Gundidza M: Screening of extracts from Zimbabwean higher plants: II.
Antifungal properties. Fitoterapia 1986, 57:111–114.
13. Iannello C, Bastida J, Bonvicini F, Antognoni F, Gentilomi GA, Poli F:
Chemical composition, and in vitro antibacterial and antifungal activity
of an alkaloid extract from Crinum angustum Steud. Nat Prod Res 2014,
28:704–710.
14. Nkanwen ERS, Gatsing D, Ngamga D, Fodouop SPC, Tane P: Antibacterial
agents from the leaves of Crinum purpurascens herb (Amaryllidaceae).
Afr Health Sci 2009, 9:264–269.
15. Valsecchi F: Le piante endemiche della Sardegna. Boll Soc Sarda Sci Nat
1982, 21:427–441.
16. Croxatto A, Prod’hom G, Greub G: Applications of MALDI-TOF mass
spectrometry in clinical diagnostic microbiology. FEMS Microbiol Rev
2012, 36:380–407.
17. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID
European Committee for Antimicrobial Susceptibility Testing (EUCAST).
EUCAST definitive document EDef 7.1: Method for the determination of
broth dilution MICs of antifungal agents for fermentative yeasts.
Clin Microbiol Infect 2008, 14:398–405.
18. Cantón E, Pemán J, Viudes A, Quindós G, Gobernado M, Espinel-Ingroff A:
Minimum fungicidal concentrations of amphotericin B for bloodstream
Candida species. Diagn Microbiol Infect Dis 2003, 45:203–206.
19. Thring TSA, Hili P, Naughton DP: Anti-collagenase, anti-elastase and
anti-oxidant activities of extracts from 21 plants. BMC Compl Altern Med
2009, 9:27–38.
20. Abraham VC, Towne DL, Waring JF, Warrior U, Burns DJ: Application of a
high-content multiparameter cytotoxicity assay to prioritize compounds
based on toxicity potential in humans. J Biomol Screen 2008, 13:527–537.
21. Cos P, Vlietinck AJ, Berghe DV, Maes L: Anti-infective potential of natural
products: how to develop a stronger in vitro ‘proof-of-concept’.
J Ethnopharm 2006, 106:290–302.
22. Ghosal S, Singh SK, Kumar Y, Unnikrishnan S, Chattopadhyay S: The role of
ungeremine in the growth-inhibiting and cytotoxic effects of lycorine:
evidence and speculation. Planta Med 1988, 54:114–116.
23. Shen JW, Ruan Y, Ren W, Ma BJ, Wang XL, Zheng CF: Lycorine: a potential
broad-spectrum agent against crop pathogenic fungi. J Microbiol
Biotechnol 2014, 24:354–358.
24. Imbert C, Kauffmann-Lacroix C, Daniault G, Jacquemin JL, Rodier MH:
Effect of matrix metalloprotease inhibitors on the 95 kDa metallopeptidase
of Candida albicans. J Antimicrob Chemother 2002, 49:1007–1010.25. dos Santos AL, de Carvalho IM, da Silva BA, Portela MB, Alviano CS, de
Araújo Soares RM: Secretion of serine peptidase by a clinical strain of
Candida albicans: influence of growth conditions and cleavage of
human serum proteins and extracellular matrix components. FEMS
Immunol Med Microbiol 2006, 46:209–220.
26. Pärnänen P, Kari K, Virtanen I, Sorsa T, Meurman JH: Human laminin-332
degradation by Candida proteinases. J Oral Pathol Med 2008, 37:329–335.
27. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F,
Murphy G, Schultz G: Analysis of the acute and chronic wound
environments: the role of proteases and their inhibitors.
Wound Repair Regen 1999, 7:442–452.
28. Arias ME, Gomez JD, Cudmani NM, Vattuone MA, Isla MI: Antibacterial
activity of ethanolic and aqueous extracts of Acacia aroma Gill. ex Hook
et Arn. Life Sci 2004, 75:191–202.
doi:10.1186/1472-6882-14-409
Cite this article as: Bonvicini et al.: Relevant and selective activity of
Pancratium illyricum L. against Candida albicans clinical isolates: a
combined effect on yeast growth and virulence. BMC Complementary
and Alternative Medicine 2014 14:409.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
